Bio-Rad Laboratories Class B
BIO.B
7 hedge funds and large institutions have $7.86M invested in Bio-Rad Laboratories Class B in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
28% more capital invested
Capital invested by funds: $6.14M → $7.86M (+$1.72M)
0.02% less ownership
Funds ownership: 0.52% → 0.51% (-0.02%)
13% less funds holding
Funds holding: 8 → 7 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$127K |
| 2 |
CF
Copperwynd Financial
Scottsdale,
Arizona
|
-$66.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CL
1
CSS LLC
Chicago,
Illinois
| $6.76M | – | – | – |
|
|
CF
2
Copperwynd Financial
Scottsdale,
Arizona
| $569K | -$66.2K | -238 | -11% |
|
3
Renaissance Technologies
New York
| $333K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $175K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $17K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
7
Morgan Stanley
New York
| – | -$127K | -550 | Closed |
|
BIO.B Hedge Fund Activity: Q1 2019 in Review
7 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q1 2019, worth a combined $7.86M — up 28% from $6.14M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIO.B and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Morgan Stanley, exiting entirely with an estimated $127K sold.
- 7 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q1 2019, down from 8 in Q4 2018.
- Funds reported $7.86M of Bio-Rad Laboratories Class B stock for Q1 2019, up 28% quarter-over-quarter.
- 0 funds opened new Bio-Rad Laboratories Class B positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest Bio-Rad Laboratories Class B seller in Q1 2019 was Morgan Stanley, an estimated $127K sold.
Based on aggregated 13F filings for Q1 2019.